The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand, offering more precise, individualized care. Here are two studies presented at EULAR 2025.
Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2025 – RA Panel Discussion
Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN
Dr. John Cush RheumNow
1 year 3 months ago
Eular 2025 PsA Topic Panel
https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76
Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2025 – SpA Panel Discussion
Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.
https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6
Dr. John Cush RheumNow
1 year 3 months ago
UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) & 311 SI deaths. MTX signif decr. SI (adj HR 0.72) & CS no effect HR 0.99. SI assoc w/ age, smoker, comorbidity, seropositive, high DAS28. 1 DAS unit incr SI https://t.co/Zmsuaf7Rw3
Dr. John Cush RheumNow
1 year 3 months ago
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY
Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.
Dr. John Cush RheumNow
1 year 3 months ago
EMA has published a concept paper about the need for guidance to inform the development of systemic sclerosis (SSc) treatments. They have identified study designs & endpoints; exploratory and confirmatory trials, and assessments of safety and efficacy. See draft here: https://t.co/WADBrw2uXe
Dr. John Cush RheumNow
1 year 3 months ago
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ
Dr. John Cush RheumNow
1 year 3 months ago
Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials
Advances in the treatment of rheumatoid arthritis (RA), particularly the treat-to-target strategy and the introduction of effective disease-modifying antirheumatic drugs (DMARDs), have improved https://t.co/cMiF6POKGS
Dr. John Cush RheumNow
1 year 3 months ago
Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL
Dr. John Cush RheumNow
1 year 3 months ago
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush RheumNow
1 year 3 months ago
Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Severity Score (MISS) >6. But MTX intolerance was NOT related to dose or route of administration, meal or time of day. These were not new MTX starters https://t.co/6KWGcZvx4o
